Truncated and modified amyloid-beta species

Alzheimer's Research and Therapy

Volumn 6, Issue 3, 2014, Pages

  Kummer, Markus P ^a   Heneka, Michael T ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GAMMA SECRETASE; NITRIC OXIDE;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; DISEASE COURSE; ENZYME ACTIVITY; GLYCOSYLATION; HUMAN; ISOMERIZATION; NITRATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RACEMIZATION; REVIEW;

EID: 84901399091     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt258     Document Type: Review

References (93)

1. Alzheimer's disease. HW Querfurth, FM LaFerla, N Engl J Med 2010 362 329 344 10.1056/NEJMra0909142 20107219
2. Decreased clearance of CNS β-amyloid in Alzheimer's disease. KG Mawuenyega, W Sigurdson, V Ovod, L Munsell, T Kasten, JC Morris, KE Yarasheski, RJ Bateman, Science 2010 330 1774 1774 10.1126/science.1197623 21148344
3. Neuroinflammatory processes in Alzheimer's disease. MT Heneka, MK O'Banion, D Terwel, MP Kummer, J Neural Transm Vienna Austria 1996 2010 117 919 947
4. Amyloid precursor protein trafficking, processing, and function. G Thinakaran, EH Koo, J Biol Chem 2008 283 29615 29619 10.1074/jbc.R800019200 18650430
5. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. P-H Kuhn, H Wang, B Dislich, A Colombo, U Zeitschel, JW Ellwart, E Kremmer, S Rossner, SF Lichtenthaler, EMBO J 2010 29 3020 3032 10.1038/emboj.2010.167 20676056
6. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. R Vassar, BD Bennett, S Babu-Khan, S Kahn, EA Mendiaz, P Denis, DB Teplow, S Ross, P Amarante, R Loeloff, Y Luo, S Fisher, J Fuller, S Edenson, J Lile, MA Jarosinski, AL Biere, E Curran, T Burgess, JC Louis, F Collins, J Treanor, G Rogers, M Citron, Science 1999 286 735 741 10.1126/science.286.5440.735 10531052 (Pubitemid 29505878)
7. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. P Seubert, C Vigo-Pelfrey, F Esch, M Lee, H Dovey, D Davis, S Sinha, M Schlossmacher, J Whaley, C Swindlehurst, Nature 1992 359 325 327 10.1038/359325a0 1406936
8. Reconstitution of gamma-secretase activity. D Edbauer, E Winkler, JT Regula, B Pesold, H Steiner, C Haass, Nat Cell Biol 2003 5 486 488 10.1038/ncb960 12679784 (Pubitemid 36592274)
9. γ-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. M Takami, Y Nagashima, Y Sano, S Ishihara, M Morishima-Kawashima, S Funamoto, Y Ihara, J Neurosci Off J Soc Neurosci 2009 29 13042 13052 10.1523/JNEUROSCI.2362-09.2009
10. Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. Y Qi-Takahara, M Morishima-Kawashima, Y Tanimura, G Dolios, N Hirotani, Y Horikoshi, F Kametani, M Maeda, TC Saido, R Wang, Y Ihara, J Neurosci Off J Soc Neurosci 2005 25 436 445 10.1523/JNEUROSCI.1575-04.2005 (Pubitemid 40105614)
11. Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides. M Bibl, M Gallus, V Welge, S Lehmann, K Sparbier, H Esselmann, J Wiltfang, Proteomics Clin Appl 2012 6 163 169 10.1002/prca.201100082 22532452
12. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. C Haass, DJ Selkoe, Nat Rev Mol Cell Biol 2007 8 101 112 10.1038/nrm2101 17245412 (Pubitemid 46432529)
13. Generation of C-terminally truncated amyloid-β peptides is dependent on γ-secretase activity. D Beher, JDJ Wrigley, AP Owens, MS Shearman, J Neurochem 2002 82 563 575 10.1046/j.1471-4159.2002.00985.x 12153480 (Pubitemid 34835674)
14. A novel pathway for amyloid precursor protein processing. E Portelius, E Price, G Brinkmalm, M Stiteler, M Olsson, R Persson, A Westman-Brinkmalm, H Zetterberg, AJ Simon, K Blennow, Neurobiol Aging 2011 32 1090 1098 10.1016/j.neurobiolaging.2009.06.002 19604603
15. β-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. C Haass, AY Hung, MG Schlossmacher, DB Teplow, DJ Selkoe, J Biol Chem 1993 268 3021 3024 8428976 (Pubitemid 23070917)
16. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. E Portelius, B Van Broeck, U Andreasson, MK Gustavsson, M Mercken, H Zetterberg, H Borghys, K Blennow, J Alzheimers Dis 2010 21 1005 1012 20634579
17. A novel Aβ isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. E Portelius, RA Dean, MK Gustavsson, U Andreasson, H Zetterberg, E Siemers, K Blennow, Alzheimers Res Ther 2010 2 7 10.1186/alzrt30 20350302
18. Alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Aβ generation. S Jäger, S Leuchtenberger, A Martin, E Czirr, J Wesselowski, M Dieckmann, E Waldron, C Korth, EH Koo, M Heneka, S Weggen, CU Pietrzik, J Neurochem 2009 111 1369 1382 10.1111/j.1471-4159.2009.06420.x 19804379
19. Unusual phenotypic alteration of beta amyloid precursor protein (βAPP) maturation by a new Val-715 → Met βAPP-770 mutation responsible for probable early-onset Alzheimer's disease. K Ancolio, C Dumanchin, H Barelli, JM Warter, A Brice, D Campion, T Frébourg, F Checler, Proc Natl Acad Sci USA 1999 96 4119 4124 10.1073/pnas.96.7.4119 10097173 (Pubitemid 29169046)
20. Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid. H Schieb, H Kratzin, O Jahn, W Möbius, S Rabe, M Staufenbiel, J Wiltfang, HW Klafki, J Biol Chem 2011 286 33747 33758 10.1074/jbc.M111.246561 21795681
21. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. N Sergeant, S Bombois, A Ghestem, H Drobecq, V Kostanjevecki, C Missiaen, A Wattez, J-P David, E Vanmechelen, C Sergheraert, A Delacourte, J Neurochem 2003 85 1581 1591 10.1046/j.1471-4159.2003.01818.x 12787077 (Pubitemid 36702570)
22. APP transgenic mice Tg2576 accumulate Aβ peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. W Kalback, MD Watson, TA Kokjohn, Y-M Kuo, N Weiss, DC Luehrs, J Lopez, D Brune, SS Sisodia, M Staufenbiel, M Emmerling, AE Roher, Biochemistry (Mosc) 2002 41 922 928 10.1021/bi015685+ (Pubitemid 34061994)
23. Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro. CJ Pike, MJ Overman, CW Cotman, J Biol Chem 1995 270 23895 23898 10.1074/jbc.270.41.23895 7592576
24. β-Amyloid degradation and Alzheimer's disease. DS Wang, DW Dickson, JS Malter, J Biomed Biotechnol 2006 2006 58406 17047308
25. Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Wiltfang, H Esselmann, P Cupers, M Neumann, H Kretzschmar, M Beyermann, D Schleuder, H Jahn, E Rüther, J Kornhuber, W Annaert, B De Strooper, P Saftig, J Biol Chem 2001 276 42645 42657 10.1074/jbc.M102790200 11526104
26. Immunohistochemical localization of amyloid beta-protein with amino-terminal aspartate in the cerebral cortex of patients with Alzheimer's disease. T Arai, H Akiyama, K Ikeda, H Kondo, H Mori, Brain Res 1999 823 202 206 10.1016/S0006-8993(98)01366-3 10095028 (Pubitemid 29225510)
27. Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. M Bibl, M Gallus, V Welge, H Esselmann, S Wolf, E Rüther, J Wiltfang, J Neural Transm Vienna Austria 1996 2012 119 805 813
28. The metalloprotease meprin β generates amino terminal-truncated amyloid β peptide species. J Bien, T Jefferson, M Causević T Jumpertz, L Munter, G Multhaup, S Weggen, C Becker-Pauly, CU Pietrzik, J Biol Chem 2012 287 33304 33313 10.1074/jbc.M112.395608 22879596
29. Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. JL Wittnam, E Portelius, H Zetterberg, MK Gustavsson, S Schilling, B Koch, H-U Demuth, K Blennow, O Wirths, TA Bayer, J Biol Chem 2012 287 8154 8162 10.1074/jbc.M111.308601 22267726
30. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. C Casas, N Sergeant, J-M Itier, V Blanchard, O Wirths, N van der Kolk, V Vingtdeux, E van de Steeg, G Ret, T Canton, H Drobecq, A Clark, B Bonici, A Delacourte, J Benavides, C Schmitz, G Tremp, TA Bayer, P Benoit, L Pradier, Am J Pathol 2004 165 1289 1300 10.1016/S0002-9440(10)63388-3 15466394 (Pubitemid 39297734)
31. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. A Güntert, H Döbeli, B Bohrmann, Neuroscience 2006 143 461 475 10.1016/j.neuroscience.2006.08.027 17008022 (Pubitemid 44716598)
32. 2+ coordination of Alzheimer's disease amyloid-beta peptide-relevance to N-terminally truncated forms. SC Drew, CL Masters, KJ Barnham, J Am Chem Soc 2009 131 8760 8761 10.1021/ja903669a 19496610
33. Amyloid plaque core protein in Alzheimer disease and Down syndrome. CL Masters, G Simms, NA Weinman, G Multhaup, BL McDonald, K Beyreuther, Proc Natl Acad Sci USA 1985 82 4245 4249 10.1073/pnas.82.12.4245 3159021 (Pubitemid 15053619)
34. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. H Lewis, D Beher, N Cookson, A Oakley, M Piggott, CM Morris, E Jaros, R Perry, P Ince, RA Kenny, CG Ballard, MS Shearman, RN Kalaria, Neuropathol Appl Neurobiol 2006 32 103 118 10.1111/j.1365-2990.2006.00696.x 16599940
35. N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Y Bouter, K Dietrich, JL Wittnam, N Rezaei-Ghaleh, T Pillot, S Papot-Couturier, T Lefebvre, F Sprenger, O Wirths, M Zweckstetter, TA Bayer, Acta Neuropathol (Berl) 2013 126 189 205 10.1007/s00401-013-1129-2
36. Amino-truncated amyloid beta-peptide (Aβ5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain. K Takeda, W Araki, H Akiyama, T Tabira, FASEB J Off Publ Fed Am Soc Exp Biol 2004 18 1755 1757 (Pubitemid 39561674)
37. A novel monoclonal antibody specific for the amino-truncated beta-amyloid Aβ5-40/42 produced from caspase-cleaved amyloid precursor protein. KS Murayama, F Kametani, T Tabira, W Araki, J Neurosci Methods 2007 161 244 249 10.1016/j.jneumeth.2006.11.010 17207535 (Pubitemid 46466952)
38. Mass spectrometric characterization of amyloid-β species in the 7PA2 cell model of Alzheimer's disease. E Portelius, M Olsson, G Brinkmalm, U Rüetschi, N Mattsson, U Andreasson, J Gobom, A Brinkmalm, M Hölttä K Blennow, H Zetterberg, J Alzheimers Dis 2013 33 85 93 22886024
39. BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system. N Mattsson, L Rajendran, H Zetterberg, M Gustavsson, U Andreasson, M Olsson, G Brinkmalm, J Lundkvist, LH Jacobson, L Perrot, U Neumann, H Borghys, M Mercken, D Dhuyvetter, F Jeppsson, K Blennow, E Portelius, PloS One 2012 7 31084 10.1371/journal.pone. 0031084 22328928
40. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Hu, A Igarashi, M Kamata, H Nakagawa, J Biol Chem 2001 276 47863 47868 11604391
41. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. J Näslund, A Schierhorn, U Hellman, L Lannfelt, AD Roses, LO Tjernberg, J Silberring, SE Gandy, B Winblad, P Greengard, Proc Natl Acad Sci USA 1994 91 8378 8382 10.1073/pnas.91.18.8378 8078890 (Pubitemid 24273667)
42. Amyloid beta-peptide spin trapping. I: peptide enzyme toxicity is related to free radical spin trap reactivity. K Hensley, M Aksenova, JM Carney, M Harris, DA Butterfield, Neuroreport 1995 6 489 492 10.1097/00001756-199502000- 00021 7766850
43. Oxidation of methionine 35 attenuates formation of amyloid beta-peptide 1-40 oligomers. M Palmblad, A Westlind-Danielsson, J Bergquist, J Biol Chem 2002 277 19506 19510 10.1074/jbc.M112218200 11912198 (Pubitemid 34967462)
44. Methionine 35 oxidation reduces fibril assembly of the amyloid Aβ-(1-42) peptide of Alzheimer's disease. L Hou, I Kang, RE Marchant, MG Zagorski, J Biol Chem 2002 277 40173 40176 10.1074/jbc.C200338200 12198111 (Pubitemid 35215584)
45. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. KJ Barnham, GD Ciccotosto, AK Tickler, FE Ali, DG Smith, NA Williamson, Y-H Lam, D Carrington, D Tew, G Kocak, I Volitakis, F Separovic, CJ Barrow, JD Wade, CL Masters, RA Cherny, CC Curtain, AI Bush, R Cappai, J Biol Chem 2003 278 42959 42965 10.1074/jbc.M305494200 12925530 (Pubitemid 37345908)
46. Phosphorylation of amyloid-beta at the serine 26 residue by human cdc2 kinase. NG Milton, Neuroreport 2001 12 3839 3844 10.1097/00001756-200112040- 00047 11726805 (Pubitemid 33105182)
47. Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. S Kumar, N Rezaei-Ghaleh, D Terwel, DR Thal, M Richard, M Hoch, JM Mc Donald, U Wüllner, K Glebov, MT Heneka, DM Walsh, M Zweckstetter, J Walter, EMBO J 2011 30 2255 2265 10.1038/emboj.2011.138 21527912
48. Early intraneuronal accumulation and increased aggregation of phosphorylated Aβ in a mouse model of Alzheimer's disease. S Kumar, O Wirths, S Theil, J Gerth, TA Bayer, J Walter, Acta Neuropathol (Berl) 2013 125 699 709 10.1007/s00401-013-1107-8
49. Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. S Kumar, S Singh, D Hinze, M Josten, H-G Sahl, M Siepmann, J Walter, J Biol Chem 2012 287 8641 8651 10.1074/jbc.M111.279133 22267728
50. Peroxynitrite reactions and formation in mitochondria. R Radi, A Cassina, R Hodara, C Quijano, L Castro, Free Radic Biol Med 2002 33 1451 1464 10.1016/S0891-5849(02)01111-5 12446202 (Pubitemid 35351588)
51. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. DA Butterfield, TT Reed, M Perluigi, C De Marco, R Coccia, JN Keller, WR Markesbery, R Sultana, Brain Res 2007 1148 243 248 17395167 (Pubitemid 46602178)
52. Proteomic identification of nitrated proteins in Alzheimer's disease brain. A Castegna, V Thongboonkerd, JB Klein, B Lynn, WR Markesbery, DA Butterfield, J Neurochem 2003 85 1394 1401 10.1046/j.1471-4159.2003.01786.x 12787059 (Pubitemid 36702552)
53. Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. MT Heneka, H Wiesinger, L Dumitrescu-Ozimek, P Riederer, DL Feinstein, T Klockgether, J Neuropathol Exp Neurol 2001 60 906 916 11556547 (Pubitemid 32880598)
54. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. Y Vodovotz, MS Lucia, KC Flanders, L Chesler, QW Xie, TW Smith, J Weidner, R Mumford, R Webber, C Nathan, AB Roberts, CF Lippa, MB Sporn, J Exp Med 1996 184 1425 1433 10.1084/jem.184.4.1425 8879214 (Pubitemid 26354698)
55. Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. MP Kummer, M Hermes, A Delekarte, T Hammerschmidt, S Kumar, D Terwel, J Walter, H-C Pape, S König, S Roeber, F Jessen, T Klockgether, M Korte, MT Heneka, Neuron 2011 71 833 844 10.1016/j.neuron.2011. 07.001 21903077
56. A central role for dityrosine crosslinking of amyloid-β in Alzheimer's disease. YK Al-Hilaly, TL Williams, M Stewart-Parker, L Ford, E Skaria, M Cole, WG Bucher, KL Morris, AA Sada, JR Thorpe, LC Serpell, Acta Neuropathol Commun 2013 1 83 10.1186/2051-5960-1-83 24351276
57. Heme binding induces dimerization and nitration of truncated β-amyloid peptide Aβ16 under oxidative stress. G Thiabaud, S Pizzocaro, R Garcia-Serres, J-M Latour, E Monzani, L Casella, Angew Chem Int Ed Engl 2013 52 8041 8044 10.1002/anie.201302989 23788407
58. Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. A Halim, G Brinkmalm, U Rüetschi, A Westman-Brinkmalm, E Portelius, H Zetterberg, K Blennow, G Larson, J Nilsson, Proc Natl Acad Sci USA 2011 108 11848 11853 10.1073/pnas.1102664108 21712440
59. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. H Mori, K Takio, M Ogawara, DJ Selkoe, J Biol Chem 1992 267 17082 17086 1512246
60. Dominant and differential deposition of distinct beta-amyloid peptide species, AβN3(pE), in senile plaques. TC Saido, T Iwatsubo, DM Mann, H Shimada, Y Ihara, S Kawashima, Neuron 1995 14 457 466 10.1016/0896-6273(95) 90301-1 7857653
61. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Sevalle, A Amoyel, P Robert, M-C Fournié-Zaluski, B Roques, F Checler, J Neurochem 2009 109 248 256 10.1111/j.1471-4159.2009.05950.x 19187443
62. Characterization of Aβ11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer's disease. K Liu, I Solano, D Mann, C Lemere, M Mercken, JQ Trojanowski, VM-Y Lee, Acta Neuropathol (Berl) 2006 112 163 174 10.1007/s00401-006-0077-5
63. Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. JT Huse, K Liu, DS Pijak, D Carlin, VM-Y Lee, RW Doms, J Biol Chem 2002 277 16278 16284 10.1074/jbc.M111141200 11847218 (Pubitemid 34967916)
64. Glu11 site cleavage and N-terminally truncated Aβ production upon BACE overexpression. K Liu, RW Doms, VM-Y Lee, Biochemistry (Mosc) 2002 41 3128 3136 10.1021/bi015800g (Pubitemid 34184644)
65. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. S Schilling, T Hoffmann, S Manhart, M Hoffmann, H-U Demuth, FEBS Lett 2004 563 191 196 10.1016/S0014-5793(04)00300-X 15063747 (Pubitemid 38471597)
66. Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology. S Schilling, U Zeitschel, T Hoffmann, U Heiser, M Francke, A Kehlen, M Holzer, B Hutter-Paier, M Prokesch, M Windisch, W Jagla, D Schlenzig, C Lindner, T Rudolph, G Reuter, H Cynis, D Montag, H-U Demuth, S Rossner, Nat Med 2008 14 1106 1111 10.1038/nm.1872 18836460
67. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. H Cynis, E Scheel, TC Saido, S Schilling, H-U Demuth, Biochemistry (Mosc) 2008 47 7405 7413 10.1021/bi800250p (Pubitemid 351991019)
68. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Aβ formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. S Jawhar, O Wirths, S Schilling, S Graubner, H-U Demuth, TA Bayer, J Biol Chem 2011 286 4454 4460 10.1074/jbc.M110.185819 21148560
69. Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of Aβ1-40 and -42. TL Tekirian, AY Yang, C Glabe, JW Geddes, J Neurochem 1999 73 1584 1589 10501204 (Pubitemid 29440160)
70. N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. I Youssef, S Florent-Béchard, C Malaplate-Armand, V Koziel, B Bihain, J-L Olivier, B Leininger-Muller, B Kriem, T Oster, T Pillot, Neurobiol Aging 2008 29 1319 1333 10.1016/j.neurobiolaging.2007.03.005 17459527 (Pubitemid 351981997)
71. The Aβ3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length Aβ W He, CJ Barrow, Biochemistry (Mosc) 1999 38 10871 10877 10.1021/bi990563r (Pubitemid 29404419)
72. Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. DZ Christensen, SL Kraus, A Flohr, M-C Cotel, O Wirths, TA Bayer, Acta Neuropathol (Berl) 2008 116 647 655 10.1007/s00401-008-0451-6
73. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. T Kawarabayashi, LH Younkin, TC Saido, M Shoji, KH Ashe, SG Younkin, J Neurosci 2001 21 372 381 11160418 (Pubitemid 32107428)
74. Intraneuronal pyroglutamate-Aβ 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. O Wirths, H Breyhan, H Cynis, S Schilling, H-U Demuth, TA Bayer, Acta Neuropathol (Berl) 2009 118 487 496 10.1007/s00401-009-0557-5
75. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. A Alexandru, W Jagla, S Graubner, A Becker, C Bäuscher, S Kohlmann, R Sedlmeier, KA Raber, H Cynis, R Rönicke, KG Reymann, E Petrasch-Parwez, M Hartlage-Rübsamen, A Waniek, S Rossner, S Schilling, AP Osmand, H-U Demuth, S von Hörsten, J Neurosci Off J Soc Neurosci 2011 31 12790 12801 10.1523/JNEUROSCI.1794-11.2011
76. Aspartate-bond isomerization affects the major conformations of synthetic peptides. GI Szendrei, H Fabian, HH Mantsch, S Lovas, O Nyéki, I Schön, L Otvos Jr, Eur J Biochem FEBS 1994 226 917 924 10.1111/j.1432-1033. 1994.t01-1-00917.x
77. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. AE Roher, JD Lowenson, S Clarke, C Wolkow, R Wang, RJ Cotter, IM Reardon, HA Zürcher-Neely, RL Heinrikson, MJ Ball, J Biol Chem 1993 268 3072 3083 8428986 (Pubitemid 23070928)
78. Synthetic post-translationally modified human Aβ peptide exhibits a markedly increased tendency to form beta-pleated sheets in vitro. H Fabian, GI Szendrei, HH Mantsch, BD Greenberg, L Otvös Jr, Eur J Biochem FEBS 1994 221 959 964 10.1111/j.1432-1033.1994.tb18811.x (Pubitemid 24146195)
79. Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease. T Shimizu, H Fukuda, S Murayama, N Izumiyama, T Shirasawa, J Neurosci Res 2002 70 451 461 10.1002/jnr.10350 12391606 (Pubitemid 35222382)
80. Synthesis, aggregation, and neurotoxicity of the Alzheimer's Aβ1-42 amyloid peptide and its isoaspartyl isomers. H Fukuda, T Shimizu, M Nakajima, H Mori, T Shirasawa, Bioorg Med Chem Lett 1999 9 953 956 10.1016/S0960-894X(99) 00121-3 10230618 (Pubitemid 29179887)
81. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Aβ peptides of Alzheimer's disease. YM Kuo, S Webster, MR Emmerling, N De Lima, AE Roher, Biochim Biophys Acta 1998 1406 291 298 10.1016/S0925-4439(98)00014-3 9630681 (Pubitemid 28269312)
82. The presence of isoaspartic acid in β-amyloid plaques indicates plaque age. MI Fonseca, E Head, P Velazquez, CW Cotman, AJ Tenner, Exp Neurol 1999 157 277 288 10.1006/exnr.1999.7058 10364440 (Pubitemid 29260736)
83. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. T Iwatsubo, TC Saido, DM Mann, VM Lee, JQ Trojanowski, Am J Pathol 1996 149 1823 1830 8952519 (Pubitemid 26415203)
84. Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer disease. T Kubo, Y Kumagae, CA Miller, I Kaneko, J Neuropathol Exp Neurol 2003 62 248 259 12638729 (Pubitemid 36330676)
85. Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues. T Tomiyama, S Asano, Y Furiya, T Shirasawa, N Endo, H Mori, J Biol Chem 1994 269 10205 10208 8144598
86. Racemization of the aspartic acid residue of amyloid-β peptide by a radical reaction. K Tambo, T Yamaguchi, K Kobayashi, E Terauchi, I Ichi, S Kojo, Biosci Biotechnol Biochem 2013 77 416 418 23391937
87. Simultaneous determination of post-translational racemization and isomerization of N-terminal amyloid-beta in Alzheimer's brain tissues by covalent chiral derivatized ultra-performance liquid chromatography tandem mass spectrometry. K Inoue, D Hosaka, N Mochiuki, H Akatsu, K Tsutsumiuchi, Y Hashizume, N Matsukawa, T Yamamoto, T Toyo'oka, Anal Chem 2013 86 797 804 24283798
88. Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient. E Portelius, MK Gustavsson, H Zetterberg, U Andreasson, K Blennow, Neurodegener Dis 2012 10 138 140 10.1159/000334537 22302034
89. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. V Welge, O Fiege, P Lewczuk, B Mollenhauer, H Esselmann, H-W Klafki, S Wolf, C Trenkwalder, M Otto, J Kornhuber, J Wiltfang, M Bibl, J Neural Transm Vienna Austria 1996 2009 116 203 212
90. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias. M Bibl, B Mollenhauer, P Lewczuk, H Esselmann, S Wolf, M Otto, J Kornhuber, E Rüther, J Wiltfang, Dement Geriatr Cogn Disord 2011 31 37 44 10.1159/000322370 21135556
91. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. M Britschgi, CE Olin, HT Johns, Y Takeda-Uchimura, MC LeMieux, K Rufibach, J Rajadas, H Zhang, B Tomooka, WH Robinson, CM Clark, AM Fagan, DR Galasko, DM Holtzman, M Jutel, JA Kaye, CA Lemere, J Leszek, G Li, ER Peskind, JF Quinn, JA Yesavage, JA Ghiso, T Wyss-Coray, Proc Natl Acad Sci USA 2009 106 12145 12150 10.1073/pnas.0904866106 19581601
92. Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease. A Marcello, O Wirths, T Schneider-Axmann, M Degerman-Gunnarsson, L Lannfelt, TA Bayer, Neurobiol Aging 2011 32 1379 1387 10.1016/j.neurobiolaging.2009.08.011 19781815
93. Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core. CP Sullivan, EA Berg, R Elliott-Bryant, JB Fishman, AC McKee, PJ Morin, MA Shia, RE Fine, Neurosci Lett 2011 505 109 112 10.1016/j.neulet.2011. 09.071 22001577